Aimabs Corporation-About Aimabs

About Aimabs

Aimabs is a biopharmaceutical company built to bridge global innovation and patient access. We partner across borders to advance and deliver transformative medicines, bringing high-impact therapies to patients with greater speed, clarity, and confidence.

With deep roots in targeted monoclonal antibody innovation, Aimabs has expanded into multiple therapeutic modalities and integrates advanced AI-enabled approaches to streamline development. Our primary focus areas include hematology, oncology, and other specialty indications with significant unmet medical need.

What sets Aimabs apart is our integrated, end-to-end capability across regulatory strategy, clinical development, and commercialization, supported by bidirectional global-local execution that connects scientific innovation to real-world clinical impact.

Mission

Core Advantage

Regulatory strategy is a defining strength at Aimabs. Our leadership has first-hand experience within top global agencies and deep expertise navigating China’s evolving regulatory landscape. This dual perspective allows us to de-risk development, accelerate timelines, and align programs with global standards from the earliest stages.

• Dual-market insight: Our Founder & CEO, Dr. Yaping Wang, is a former U.S. FDA Senior Reviewer (Oncology Center of Excellence) and a trusted advisor to China’s CDE/NMPA. We bring strong command of FDA, NMPA, and ICH requirements, with practical guidance on emerging policy trends.

• Cross-border strategic planning: We design clinical strategies and submission packages built to satisfy multi-region expectations, helping partners reduce rework and maximize global optionality.

• Quality and compliance: Our globally aligned Quality Management System supports inspection readiness, data integrity, and long-term compliance across ICH, FDA, and NMPA standards.

Regulatory Excellence

Aimabs brings decades of hands-on experience across all stages of drug development—from early discovery through late-stage validation and launch preparation. We combine scientific rigor, clinical insight, and operational excellence to improve execution quality and increase probability of success.

• Clinical development leadership: Dr. Michael Humphries (SVP & Chief Medical Officer) has 30+ years of global and Asia-Pacific development experience and has contributed to 50+ NDA approvals in China and international markets.

• Operational excellence: Dr. Jean Zhang (VP, Clinical Operations) brings 30+ years of leadership experience at Novartis, Pfizer, and AstraZeneca, with expertise in clinical quality, pharmacovigilance, and trial execution across regions.

• AI-enabled acceleration: We apply AI and machine learning to enhance trial design, patient recruitment strategy, and data analytics—accelerating readiness for global out-licensing and improving efficiency for Greater China development.

Drug Development Expertise

Aimabs partners with CiNS, a leading oncology/hematology-focused commercial organization in Greater China, trusted by multinational companies including Eli Lilly, Pierre Fabre, and Otsuka.

• Market access & coverage: Established footprint across 400+ leading oncology hospitals and 200+ hematology hospitals, supporting broad access to specialty care.

• Sales & launch execution: 150+ specialized commercial professionals supported by cross-functional infrastructure (marketing, PV, RA) to enable high-quality launches.

• Operational readiness: Mature import/trade capabilities, supply chain coordination, and tender management expertise to support long-term growth in China.

Commercialization

Capability

Global Expertise, China Execution

Aimabs supports both inbound and outbound commercialization strategies through a highly execution-driven partnership model.

• Inbound (Greater China): For U.S. and global biotech partners, Aimabs provides local development, registration, and commercialization capabilities to unlock value in Greater China.

• Outbound (U.S./EU and Global): For China-based innovators, we help prepare and position early-stage assets to meet global expectations—supporting out-licensing and strategic partnering in Western markets.

Global Partnership